36,686 results match your criteria Lymphoma Diffuse Large Cell

Proteomic analysis in diffuse large B-cell lymphoma identifies dysregulated tumor microenvironment proteins in non-GCB/ABC subtype patients.

Leuk Lymphoma 2021 Jun 11:1-14. Epub 2021 Jun 11.

Department of Medicine, Section of Hematology, South Älvsborg Hospital, Borås, Sweden.

The complexity of the activated B-cell like (ABC) diffuse large B-cell lymphoma (DLBCL) subtype is probably not only explained by genetic alterations and methods to measure global protein expression could bring new knowledge regarding the pathophysiology. We used quantitative proteomics to analyze the global protein expression of formalin-fixed paraffin-embedded (FFPE) tumor tissues from 202 DLBCL patients. We identified 6430 proteins and 498 were significantly regulated between the germinal center B-cell like (GCB) and non-GCB groups. Read More

View Article and Full-Text PDF

Clinical and prognostic role of sarcopenia in elderly patients with classical Hodgkin lymphoma: a multicentre experience.

J Cachexia Sarcopenia Muscle 2021 Jun 11. Epub 2021 Jun 11.

Division of Hematology, ASST Spedali Civili, Brescia, Italy.

Background: Elderly classical Hodgkin lymphoma (cHL) (ecHL) is a rare disease with dismal prognosis and no standard treatment. Fitness-based approaches may help design appropriate treatments. Sarcopenia has been associated with an increased risk of treatment-related toxicities and worse survival in various solid tumours, but its impact in ecHL is unknown. Read More

View Article and Full-Text PDF

-Generated CAR19-T Cells Plus Lenalidomide Cause Durable Complete Remission of Triple-Hit Refractory/Relapsed DLBCL: A Case Report.

Front Immunol 2021 25;12:599493. Epub 2021 May 25.

Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

MYC/BCL2/BCL6 triple-hit lymphoma (THL) is an uncommon subset of high-grade B-cell lymphoma with aggressive clinical behavior and poor prognosis. TP53 mutation is an independently poor progonistic indicator in patients with THL, hence novel therapeutic strategies are needed for these patients. CD19-directed chimeric antigen receptor(CAR19)-T cell therapy has shown promising efficacy for relapsed/refractory diffuse large B cell lymphoma (RR DLBCL), but the majority of CAR19-T cell products to date have been manufactured using viral vectors. Read More

View Article and Full-Text PDF

The regulation of miR-320a/XBP1 axis through LINC00963 for endoplasmic reticulum stress and autophagy in diffuse large B-cell lymphoma.

Cancer Cell Int 2021 Jun 10;21(1):305. Epub 2021 Jun 10.

School of Basic Medicine, Jiamusi University, Jiamusi, 154007, Heilongjiang, China.

Background: This study incorporates fundamental research referring to considerable amounts of gene-sequencing data and bioinformatics tools to analyze the pathological mechanisms of diffuse large B-cell lymphoma (DLBCL).

Methods: A lncRNA-miRNA-mRNA ceRNA network of DLBCL was constructed through database analysis combining GTEx and TCGA. qPCR was used to detect the expression of LINC00963 and miR-320a in DLBCL cell lines. Read More

View Article and Full-Text PDF

Ibalizumab-uiyk as a bridge therapy for a patient with drug-resistant HIV-1 infection receiving chemotherapy: A case report.

J Clin Pharm Ther 2021 Jun 10. Epub 2021 Jun 10.

Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USA.

What Is Known And Objective: Treatment for diffuse large B-cell lymphoma (DLBCL) in persons with AIDS consists of chemotherapy alongside antiretroviral therapy (ART). To determine optimal HIV treatment, drug-drug interactions, toxic effects and ART resistance must be considered.

Case Description: A 40-year-old man with drug-resistant HIV and DLBCL initiating chemotherapy which had drug interactions with his ART. Read More

View Article and Full-Text PDF

Differential expression of miRNAs as biomarkers for predicting the outcomes of diffuse large B-cell lymphoma patients.

Biosci Rep 2021 Jun 10. Epub 2021 Jun 10.

Anhui Provincial Hospital, Hefei, China.

Background: Diffuse large B-cell lymphoma used to be defined as germinal center B-like and non-germinal center B-like subtypes, associated with different prognoses, but the conventional classification does not meet the needs of clinical practice because of diffuse large B-cell lymphoma heterogeneity, a problem that might be improved by selection of miRNAs as biomarkers.

Methods: Twelve patients with diffuse large B-cell lymphomas were used to screen out the aberrant miRNA profile using miRNA microarray technology in 2 patient subtypes (6 germinal center B-like and 6 non-germinal center B-like patients). The potential biomarkers were further analyzed using the quantitative reverse transcription-polymerase chain reaction method in 95 diffuse large B-cell lymphoma patients to investigate relationships between expression levels of potent miRNA, clinicopathological features, and survival rates of patients. Read More

View Article and Full-Text PDF

[Molecular classification of aggressive B-cell lymphoma].

Daisuke Ennishi

Rinsho Ketsueki 2021 ;62(5):418-423

Center for Comprehensive Genomic Medicine, Okayama University Hospital.

Diffuse large B-cell lymphoma (DLBCL) is a clinically and biologically highly heterogeneous disease; various molecular genetic abnormalities contribute to DLBCL development. In particular, recent advances in genomics technologies have led to the discovery of unknown genetic abnormalities and gene expression patterns. Based on the identified pathophysiologies, molecular sub-classification of DLBCL has been progressing. Read More

View Article and Full-Text PDF

[Primary breast diffuse large B-cell lymphoma in an elderly man maintaining long-term complete response].

Rinsho Ketsueki 2021 ;62(5):341-345

Department of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine.

Primary breast diffuse large B-cell lymphoma (DLBCL) is a rare non-Hodgkin's lymphoma that mostly affects women. Here, we report a case of primary breast DLBCL that affected an older man without any autoimmune disease or drug-related female hormones. The patient was a 65-year-old man whose chief complaints were gradually-increasing lump in the right chest and swelling of the right axillary lymph nodes. Read More

View Article and Full-Text PDF

Diffuse Large B-Cell Lymphoma. Reply.

N Engl J Med 2021 06;384(23):2262

Memorial Sloan Kettering Cancer Center, New York, NY.

View Article and Full-Text PDF

Diffuse Large B-Cell Lymphoma.

N Engl J Med 2021 06;384(23):2261-2262

University of Calgary, Calgary, AB, Canada

View Article and Full-Text PDF

Clinicopathological analysis of primary refractory diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone chemoimmunotherapy.

Cancer Med 2021 Jun 9. Epub 2021 Jun 9.

Department of Hematology, National Cancer Center Hospital, Tokyo, Japan.

Background: Approximately 15% of patients with diffuse large B-cell lymphoma (DLBCL) experience refractory or early relapsed disease after initial rituximab-containing chemoimmunotherapy is regarded as a primary refractory disease. Although the standard treatment for relapsed DLBCL is high-dose chemotherapy and autologous stem cell transplantation (HDC-ASCT), the efficacy of this approach for primary refractory DLBCL is not well understood. We aimed to investigate the clinicopathological characteristics and outcomes of patients with primary refractory DLBCL. Read More

View Article and Full-Text PDF

Molecular classification of aggressive lymphomas-past, present, future.

Hematol Oncol 2021 Jun;39 Suppl 1:24-30

Department of Hematology and Medical Oncology, University Medical Center Göttingen, Göttingen, Germany.

Aggressive large B-cell lymphomas (LBCLs) represent a frequent but clinically and molecularly heterogeneous group of tumors. Technological advances over the last decades prompted the development of different classification schemas to either sharpen diagnoses, dissect molecular heterogeneity, predict outcome, or identify rational treatment targets. Despite increased diagnostic precision and a noticeably improved molecular understanding of these lymphomas, clinical perspectives of patients largely remain unchanged. Read More

View Article and Full-Text PDF

[Relationship between Polymorphism of miR-155 and Its Target Gene MyD88 and Clinicopathological Features of Diffuse Large B-cell Lymphoma].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2021 Jun;29(3):757-762

Department of Hematology, The First Hospital of Handan City, Handan 056002, Hebei Province, China.

Objective: To investigate the relationship between the polymorphism of miR-155 and its target gene MyD88 and clinicopathological features of diffuse large B-cell lymphoma (DLBCL).

Methods: 135 cases of DLBCL patients in our hospital from March 2015 to August 2017 were selected, and 90 cases of reactive hyperplasia of lymph nodes were selected as the control group. The relative expression of miR-155 and MyD88 gene polymorphism were detected in the two groups, and the relationship between miR-155 and MyD88 gene polymorphism and clinicopathological characteristics of DLBCL was analyzed. Read More

View Article and Full-Text PDF

[Analysis of the Predictive Value of EZH2 Expression Level on the Clinical Efficacy and Long-term Prognosis of Patients with Primary Gastrointestinal Diffuse Large B-cell Lymphoma].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2021 Jun;29(3):725-730

Department of Lymphoma and Head and Neck Cancer, The Affiliated Tumor Hospital of Fujian Medical University, Fuzhou 350014, Fujian Province, China.

Objective: To investigate the predictive value of methyltransferase EZH2 expression level on the clinical efficacy and long-term prognosis of patients with primary gastrointestinal diffuse large B-cell lymphoma (PGI-DLBCL).

Methods: 161 patients with newly treated PGI-DLBCL in our hospital from August 2013 to July 2019 were selected. The expression level of EZH2 protein was detected by immunohistochemistry, and the short-term efficacy and long-term survival differences of patients with different levels of EZH2 were compared. Read More

View Article and Full-Text PDF

A rare case of primary cutaneous diffuse large B-cell lymphoma, leg type, presenting as cellulitis: a case report.

J Surg Case Rep 2021 Jun 4;2021(6):rjab227. Epub 2021 Jun 4.

Division of Plastic Surgery, Department of Surgery, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.

Primary cutaneous diffuse large B-cell lymphoma, leg type, accounts for only 4% of all cutaneous lymphomas and bears a worse prognosis than other cutaneous B-cell lymphomas. Diagnosis at an early stage may be difficult due to its nonspecific manifestations. We report an 88-year-old female who was brought to our emergency department due to two rapidly growing painful skin lesions with local redness and swelling on her right lower leg. Read More

View Article and Full-Text PDF

Maintenance therapy for untreated diffuse large B-cell lymphoma: a systematic review and network meta-analysis.

Ther Adv Hematol 2021 29;12:20406207211018894. Epub 2021 May 29.

Epidemiology and Health Statistics, School and Hospital of Stomatology, Cheeloo College of Medicine, Shandong University & Shandong Key Laboratory of Oral Tissue Regeneration & Shandong Engineering Laboratory for Dental Materials and Oral Tissue Regeneration, No. 44-1, Wenhua Road West, Jinan, Shandong 250012, P.R. China.

Background: Several clinical trials have been conducted to evaluate the role of maintenance therapy in untreated diffuse large B-cell lymphoma (DLBCL) patients with complete response or partial response following standard immunochemotherapy; however, the effect of maintenance therapy remains uncertain, and a suitable maintenance strategy has not been determined because of the lack of direct/indirect comparisons.

Methods: We performed a systematic review and Bayesian network meta-analysis (NMA) to analyze and compare the effectiveness of different maintenance regimens in newly diagnosed DLBCL patients. We searched the , , , , and for relevant papers from inception to 18 March 2021. Read More

View Article and Full-Text PDF

Prognostic molecular biomarkers in diffuse large B-cell lymphoma in the rituximab era and their therapeutic implications.

Ther Adv Hematol 2021 24;12:20406207211013987. Epub 2021 May 24.

Second Department of Internal Medicine and Research Unit, Hematology Unit, University General Hospital, 'Attikon', Haidari, Athens, Greece.

Diffuse large B-cell lymphoma (DLBCL) represents a group of tumors characterized by substantial heterogeneity in terms of their pathological and biological features, a causal factor of their varied clinical outcome. This variation has persisted despite the implementation of rituximab in treatment regimens over the last 20 years. In this context, prognostic biomarkers are of great importance in order to identify high-risk patients that might benefit from treatment intensification or the introduction of novel therapeutic agents. Read More

View Article and Full-Text PDF

Prognostic significance of CD30 expression in diffuse large B cell lymphoma: A systematic review with meta-analysis.

J Oral Pathol Med 2021 Jun 8. Epub 2021 Jun 8.

Department of Oral Diagnosis, Piracicaba Dental School, University of Campinas, Piracicaba, Brazil.

Background: CD30 is variably expressed in diffuse large B cell lymphoma (DLBCL), but its prognostic potential for the affected patients remains debatable and unclear. Therefore, we aimed to determine the frequency of CD30 expression in DLBCL and its potential for prognostic determination.

Methods: An electronic systematic review was performed using multiple databases, followed by a quantitative meta-analysis to assess the frequency of CD30 expression with a positivity cut-off values of > 0% and > 20%, and to determine its association with clinicopathological features and patients' survival. Read More

View Article and Full-Text PDF

Single-Center Analysis of Characteristics and Outcomes of De Novo, Concurrent, and Transformed Diffuse Large B-Cell Lymphoma.

Oncologist 2021 Jun 7. Epub 2021 Jun 7.

Department of Hematology and Medical Oncology, Medstar Washington Hospital Center, Washington, DC, USA.

Outcomes of diffuse large B-cell lymphoma (DLBCL), either concurrent with or transformed from indolent lymphoma, treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone are described in retrospective studies. The efficacy of other regimens in transformed or concurrent DLBCL is largely unknown. In this single-center retrospective study, we present characteristics of concurrent and transformed DLBCL and outcomes after dose-adjusted etoposide, vincristine, cyclophosphamide, prednisone, and doxorubicin with rituximab (DA-EPOCH-R) comparative with de novo DLBCL. Read More

View Article and Full-Text PDF

Differentiating Primary Pancreatic Lymphoma Versus Primary Splenic Lymphoma: A Case Report.

J Pancreat Cancer 2021 29;7(1):20-22. Epub 2021 Mar 29.

Department of Surgery, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA.

Both primary pancreatic lymphoma (PPL) and primary splenic lymphoma (PSL) represent rare entities. PPL typically arises in the head of the pancreas but may arise in other locations also. PSL usually presents with nonspecific symptoms, including left upper quadrant pain, weight loss, and fever. Read More

View Article and Full-Text PDF

The Vanishing Adrenal Glands: A Transient Regression of Adrenal Lymphoma After a Single Dose of 1 mg Dexamethasone.

AACE Clin Case Rep 2021 Mar-Apr;7(2):109-112. Epub 2020 Dec 28.

Imperial Centre for Endocrinology and Diabetes, Imperial College Healthcare NHS Trust, London, United Kingdom.

Objective: Dexamethasone is a known treatment for lymphoma, but the potency and rapidity of its effect have not been recognized. We present a case of bilateral adrenal lymphoma that significantly reduced in size after a single dose of dexamethasone.

Methods: We present the clinical course and investigations, including adrenocorticotropic hormone, cortisol, short synacthen test, computed tomography (CT), and adrenal biopsy results. Read More

View Article and Full-Text PDF
December 2020

Primary age-related EBV-associated effusion-based lymphoma successfully treated with rituximab and thoracentesis.

Clin Case Rep 2021 May 4;9(5):e03971. Epub 2021 Apr 4.

Department of Pathology and Laboratory Medicine Mayo Clinic Florida Jacksonville FL USA.

EBV-positive HHV8-negative EBL is part of the spectrum of EBV-positive diffuse large B-cell lymphoma NOS. This entity can be labeled as primary age-related EBV-associated EBL and appears to respond well to rituximab and thoracentesis. Read More

View Article and Full-Text PDF

FUT8 and Protein Core Fucosylation in Tumours: From Diagnosis to Treatment.

J Cancer 2021 13;12(13):4109-4120. Epub 2021 May 13.

Special Key Laboratory of Oral Disease Research, Higher Education Institution in Guizhou Province, School of Stomatology, Zunyi Medical University, Zunyi 563006, China.

Glycosylation changes are key molecular events in tumorigenesis, progression and glycosyltransferases play a vital role in the this process. FUT8 belongs to the fucosyltransferase family and is the key enzyme involved in N-glycan core fucosylation. FUT8 and/or core fucosylated proteins are frequently upregulated in liver, lung, colorectal, pancreas, prostate,breast, oral cavity, oesophagus, and thyroid tumours, diffuse large B-cell lymphoma, ependymoma, medulloblastoma and glioblastoma multiforme and downregulated in gastric cancer. Read More

View Article and Full-Text PDF

Long noncoding RNA FIRRE contributes to the proliferation and glycolysis of hepatocellular carcinoma cells by enhancing PFKFB4 expression.

J Cancer 2021 13;12(13):4099-4108. Epub 2021 May 13.

Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China.

Recent reports show that long noncoding RNA (lncRNA) FIRRE contributes to the proliferation, apoptosis resistance, and invasion of colorectal cancer and diffuse large B-cell lymphoma. However, the biological function of FIRRE in hepatocellular carcinoma (HCC) remains unknown. Here, we disclosed that the FIRRE level was frequently increased in HCC compared to nontumor tissues. Read More

View Article and Full-Text PDF

Aggregative Perivascular Tumor Cell Growth Pattern of Primary Central Nervous System Lymphomas Is Associated with Hypoxia-Related Endoplasmic Reticulum Stress.

J Cancer 2021 5;12(13):3841-3852. Epub 2021 May 5.

Department of Hematology, Changhai Hospital, Shanghai 200433, China.

Primary central nervous system lymphomas (PCNSLs) often present a unique histopathological feature of aggregative perivascular tumor cells (APVT). Our previous studies showed that patients of PCNSL with APVTs exhibited poor long-term outcomes and increased expression of the endoplasmic reticulum stress (ERS) factor X-box-binding protein (XBP1). However, very little is known about molecular mechanism of the APVT formation in PCNSLs. Read More

View Article and Full-Text PDF

Real-World, Single-Center Data for Lenalidomide Plus Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Transformed Follicular Lymphoma.

Cancer Manag Res 2021 28;13:4241-4250. Epub 2021 May 28.

Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

Background: This study explored the efficacy of lenalidomide plus rituximab for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) including cases of secondary central nervous system (CNS) involvement and transformed follicular lymphoma (FL) in real-world context because of anti-tumor effect and blood-brain barrier permeability of lenalidomide.

Methods: Twenty-four patients including relapsed or refractory DLBCL (n = 21) including seven patients with secondary CNS involvement and transformed FL (n = 3) were retrospectively analyzed.

Results: Based on the best response, the complete response (CR) rate was 21% (5/24) and the overall response rate (ORR) was 38% (9/24). Read More

View Article and Full-Text PDF

Oral and oropharyngeal lymphomas: a multi-institutional collaborative study.

J Oral Pathol Med 2021 Jun 6. Epub 2021 Jun 6.

Department of Oral Surgery and Pathology, School of Dentistry, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.

Background: Lymphomas in the oral and oropharyngeal regions are relatively uncommon and their diagnosis is challenging and complex due to the myriad histopathological subtypes. Herein, we report a large series of oral and oropharyngeal lymphomas and compare our data with the currently available literature.

Methods: All cases diagnosed as lymphomas affecting the oral and oropharyngeal regions were retrospectively retrieved from seven Brazilian institutions. Read More

View Article and Full-Text PDF

Mature t/nk-cell lymphomas of the oral and maxillofacial region: a multi-institutional collaborative study.

J Oral Pathol Med 2021 Jun 5. Epub 2021 Jun 5.

Department of Oral Diagnosis and Pathology, School of Dentistry, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.

Background: The diagnosis of oral and maxillofacial mature T/NK-cell neoplasms is challenging because of their rarity, morphological heterogeneity and complex immunophenotype, with scarce available data describing their clinical and microscopic aspects. Therefore, in this study we investigated a series of mature T/NK-cell neoplasms affecting this anatomical region and provided an updated literature review.

Methods: Cases diagnosed as mature T/NK cell lymphomas affecting the oral and maxillofacial region were retrospectively retrieved from six pathology files and their diagnoses were confirmed using haematoxylin and eosin-stained slides, immunohistochemical reactions and in situ hybridization for Epstein-Barr virus (EBV) detection. Read More

View Article and Full-Text PDF

Infused autograft-absolute lymphocyte count predicts superior survival in Diffuse Large B-Cell Lymphoma patients post-autologous peripheral blood hematopoietic stem cell transplantation: a matched-control study.

Transplant Cell Ther 2021 Jun 3. Epub 2021 Jun 3.

Department of Medical Oncology, Mayo Clinic, Rochester, Minnesota.

Background: Our group published a double phase III trial showing that patients infused with an autograft absolute lymphocyte count (A-ALC) ≥ 0.5 × 10 cells/kg experienced superior survival post- autologous peripheral blood hematopoietic stem cell transplantation (APBHSCT). Based on the results from our phase III study as well as published retrospective studies, on April 1, 2017, our Bone Marrow Transplant Program changed our standard practice to collect an A-ALC ≥ 0. Read More

View Article and Full-Text PDF

Multiple primary malignancies: synchronous lymphoma, pancreatic neuroendocrine tumour and colorectal cancer.

BMJ Case Rep 2021 Jun 4;14(6). Epub 2021 Jun 4.

Orthopedic Surgery, Hôpital Riviera-Chablais, Rennaz, Switzerland.

A 67-year-old woman underwent a medical check-up by her general practitioner after complaining of atypical pain in the shoulder girdle. Due to the important inflammatory syndrome noticed on blood testing, a polymyalgia rheumatica was suspected and she was started on corticosteroid treatment with good clinical response, but no impact on inflammation. She underwent extensive imaging with a thoraco-abdominal CT scanner that demonstrated a pancreatic mass, then later a PET-CT showed 3 different hyperactive lesions. Read More

View Article and Full-Text PDF